Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

MLA

Takashi Ueda, et al. “Abiraterone Acetate versus Bicalutamide in Combination with Gonadotropin Releasing Hormone Antagonist Therapy for High Risk Metastatic Hormone Sensitive Prostate Cancer.” Scientific Reports, vol. 11, no. 1, May 2021, pp. 1–6. EBSCOhost, https://doi.org/10.1038/s41598-021-89609-2.

APA

Takashi Ueda, Takumi Shiraishi, Saya Ito, Munehiro Ohashi, Toru Matsugasumi, Yasuhiro Yamada, Atsuko Fujihara, Fumiya Hongo, Koji Okihara, & Osamu Ukimura. (2021). Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer. Scientific Reports, 11(1), 1–6. https://doi.org/10.1038/s41598-021-89609-2

Chicago

Takashi Ueda, Takumi Shiraishi, Saya Ito, Munehiro Ohashi, Toru Matsugasumi, Yasuhiro Yamada, Atsuko Fujihara, Fumiya Hongo, Koji Okihara, and Osamu Ukimura. 2021. “Abiraterone Acetate versus Bicalutamide in Combination with Gonadotropin Releasing Hormone Antagonist Therapy for High Risk Metastatic Hormone Sensitive Prostate Cancer.” Scientific Reports 11 (1): 1–6. doi:10.1038/s41598-021-89609-2.